177 related articles for article (PubMed ID: 22247499)
1. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood.
Klee EW; Bondar OP; Goodmanson MK; Dyer RB; Erdogan S; Bergstralh EJ; Bergen HR; Sebo TJ; Klee GG
Clin Chem; 2012 Mar; 58(3):599-609. PubMed ID: 22247499
[TBL] [Abstract][Full Text] [Related]
2. Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
Bai VU; Hwang O; Divine GW; Barrack ER; Menon M; Reddy GP; Hwang C
PLoS One; 2012; 7(4):e34875. PubMed ID: 22493721
[TBL] [Abstract][Full Text] [Related]
3. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.
Leiblich A; Cross SS; Catto JW; Pesce G; Hamdy FC; Rehman I
Prostate; 2007 Dec; 67(16):1761-9. PubMed ID: 17929277
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
5. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
Rabien A; Fritzsche F; Jung M; Diamandis EP; Loening SA; Dietel M; Jung K; Stephan C; Kristiansen G
Tumour Biol; 2008; 29(1):1-8. PubMed ID: 18497543
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
[TBL] [Abstract][Full Text] [Related]
7. Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.
Shah AK; Cao KA; Choi E; Chen D; Gautier B; Nancarrow D; Whiteman DC; Saunders NA; Barbour AP; Joshi V; Hill MM
Mol Cell Proteomics; 2015 Nov; 14(11):3023-39. PubMed ID: 26404905
[TBL] [Abstract][Full Text] [Related]
8. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.
Basu A; Banerjee H; Rojas H; Martinez SR; Roy S; Jia Z; Lilly MB; De León M; Casiano CA
Prostate; 2011 May; 71(7):755-65. PubMed ID: 21031435
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.
Zeng X; Hood BL; Sun M; Conrads TP; Day RS; Weissfeld JL; Siegfried JM; Bigbee WL
J Proteome Res; 2010 Dec; 9(12):6440-9. PubMed ID: 20931982
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction.
Pinzani P; Lind K; Malentacchi F; Nesi G; Salvianti F; Villari D; Kubista M; Pazzagli M; Orlando C
Hum Pathol; 2008 Oct; 39(10):1474-82. PubMed ID: 18619642
[TBL] [Abstract][Full Text] [Related]
13. A role for STEAP2 in prostate cancer progression.
Whiteland H; Spencer-Harty S; Morgan C; Kynaston H; Thomas DH; Bose P; Fenn N; Lewis P; Jenkins S; Doak SH
Clin Exp Metastasis; 2014 Dec; 31(8):909-20. PubMed ID: 25248617
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males.
Ahmed MI; Abd-Elmotelib F; Farag RM; Ziada NA; Khalifa A
Clin Biochem; 1999 Aug; 32(6):439-45. PubMed ID: 10667479
[TBL] [Abstract][Full Text] [Related]
15. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis.
Cheung PK; Woolcock B; Adomat H; Sutcliffe M; Bainbridge TC; Jones EC; Webber D; Kinahan T; Sadar M; Gleave ME; Vielkind J
Cancer Res; 2004 Sep; 64(17):5929-33. PubMed ID: 15342369
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
17. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Kristiansen G; Fritzsche FR; Wassermann K; Jäger C; Tölls A; Lein M; Stephan C; Jung K; Pilarsky C; Dietel M; Moch H
Br J Cancer; 2008 Sep; 99(6):939-48. PubMed ID: 18781151
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15.
Tekin B; Dasari S; Theis JD; Vrana JA; Murray DL; Oglesbee D; Thompson RH; Leibovich BC; Boorjian SA; Whaley RD; Hernandez LH; Jimenez RE; Cheville JC; Karnes RJ; Sukov WR; Gupta S
Hum Pathol; 2023 May; 135():35-44. PubMed ID: 36906183
[TBL] [Abstract][Full Text] [Related]
19. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
20. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
